Company Filing History:
Years Active: 2023
Title: Karam F A Soliman: Innovator in Anti-Mitotic Drug Development
Introduction
Karam F A Soliman is a notable inventor based in Tallahassee, FL (US). He has made significant contributions to the field of cancer research, particularly in developing treatments for triple negative breast cancer (TNBC). His innovative work has led to the creation of a patent that addresses critical challenges in cancer therapy.
Latest Patents
Karam F A Soliman holds a patent for "Substituted tetrahydroisoquinolines as anti-mitotic drug in triple negative breast cancer." This patent presents novel compositions and methods for using these compositions to treat TNBC. The compound 4-Ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide has demonstrated the ability to downregulate the expression of several genes associated with TNBC, including amphiregulin (AREG), epiregulin (EREG), inhibitor of DNA binding 1 (ID1), inhibitor of DNA binding 3 (ID3), killer cell lectin like receptor C3 (KLRC3), cyclooxygenase-2 (COX2), and intercellular adhesion molecule 1 (ICAM-1). Additionally, this compound has been shown to downregulate the oncostatin M (OSM) signaling pathway, highlighting its potential as a therapeutic agent.
Career Highlights
Karam F A Soliman is affiliated with Florida A&M University, where he continues to engage in research and development in the field of cancer treatment. His work is characterized by a commitment to advancing medical science and improving patient outcomes through innovative drug development.
Collaborations
Karam has collaborated with notable colleagues, including Kinfe Ken Redda and Madhavi Gangapuram. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Karam F A Soliman's contributions to the field of anti-mitotic drug development represent a significant advancement in the fight against triple negative breast cancer. His innovative approaches and dedication to research continue to inspire progress in cancer treatment.